VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials

VGTI Florida to coordinate cancer study design and trial sites selection November 18, 2014 The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc., forming a partnership to advance TapImmune’s proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment …

TapImmune’s New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens

August 7th, 2014 TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones …

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev

June 17, 2014 PsiOxus Therapeutics Ltd., an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first dosing of a patient in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study. OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at multiple UK cancer centres beginning …

Immunovaccine’s Novel Immunotherapy Triggers Partial Response and Generates Potent Immune Responses in Ovarian Cancer Clinical Study

Company to Highlight Promising Clinical Activity of DPX-Survivac Cancer Vaccine at 2014 ASCO Annual Meeting May 20, 2014 Immunovaccine Inc., a clinical stage vaccine company, announced today that new positive clinical data on the Company’s lead cancer vaccine candidate, DPX-Survivac, will be presented as a poster at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June …

Moffitt Cancer Center Begins Phase I Clinical Trial of New Immunotherapy

April 9, 2014 Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective …

Novel Cancer Vaccine Holds Promise Against Ovarian Cancer, Mesothelioma

March 5, 2014 A novel approach to cancer immunotherapy – strategies designed to induce the immune system to attack cancer cells – may provide a new and cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. Investigators from the Massachusetts General Hospital (MGH) Vaccine and Immunotherapy Center report in the Journal of Hematology & Oncology that a …

Personalized ovarian cancer vaccine trial results look promising

A new ovarian cancer vaccine has shown promise in clinical trials. The cancer vaccine relies on an innovative two-step immunotherapy approach, the first step of which is to manufacture a personalized dendritic cell vaccine by exposing the patient's dendritic cells to tumour tissue collected during surgery. The primed dendritic cells are then sent back into the body to raise the …